Oberweis Asset Management Inc. Grows Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Oberweis Asset Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 18.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 237,200 shares of the company's stock after purchasing an additional 36,200 shares during the quarter. Oberweis Asset Management Inc. owned 0.33% of Kiniksa Pharmaceuticals worth $4,692,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth about $158,000. Tower Research Capital LLC TRC raised its position in Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after purchasing an additional 4,575 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after buying an additional 1,004 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after acquiring an additional 719 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $258,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.11 during trading hours on Monday, hitting $21.47. 545,053 shares of the company were exchanged, compared to its average volume of 465,596. The company has a 50 day simple moving average of $21.15 and a two-hundred day simple moving average of $21.31. The firm has a market cap of $1.56 billion, a P/E ratio of -153.35 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's revenue for the quarter was up 46.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 earnings per share. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares of the company's stock, valued at $595,553.60. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 8,879 shares of the company's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares of the company's stock, valued at $540,124.20. The trade was a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,025 shares of company stock valued at $2,372,610. Company insiders own 54.57% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.